Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

04 June 2020

Experts over... het antibioticatekort

This article, written in Dutch by Jenny Hasenack for Chemie Mediacentrum, looks into the issue of generic medicine production, and specifically antibiotics, in China and Europe.

Direct links

Read the full article

The article looks into the reasons why production of many generic medicines has recently moved to China rather than keeping such production local within Europe. The author notes that with the exception of one factory in Austria, no antibiotics have been produced in Europe since the 1990s. 

Marijn Verhoef, Company Engagement Manager at the Access to Medicine Foundation, is quoted noting that limiting antibiotic production to certain geographic areas, or even to specific factories, can lead to global shortages of medicines in the event of unexpected issues. As an example of this, Verhoef refers to an explosion in  Chinese factory that caused a worldwide shortage of the antibiotic because the API was only produced in that specific factory.

The article discusses the issue of antimicrobial resistance and the logistics of moving antibiotic production factories back to Europe. Finally, the piece wraps up by discussing how the current COVID-19 pandemic could impact the future of medicine production. 

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved